Welcome to our dedicated page for Candel Therapeutics SEC filings (Ticker: CADL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Candel Therapeutics, Inc. (CADL) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Candel is a clinical-stage biopharmaceutical company whose common stock trades on the Nasdaq Global Market under the symbol CADL, as noted in multiple Form 8-K filings. Its filings document material events related to its multimodal viral immunotherapy programs, capital structure, and key agreements.
Investors can review current reports on Form 8-K describing clinical and corporate milestones, such as interim data from the phase 1b trial of CAN-3110 in recurrent glioblastoma, progress with CAN-2409 in localized prostate cancer, NSCLC, and PDAC, and strategic decisions to prioritize certain indications. Other 8-K filings outline financing arrangements, including a Loan and Security Agreement with Trinity Capital Inc. for up to $130 million in term loans, registered direct equity offerings under an effective shelf registration statement, warrant amendments, and lease extensions for facilities in Needham, Massachusetts.
These filings also identify when Candel issues press releases on quarterly financial results, R&D events, and material agreements, and they confirm that CADL common stock is registered under Section 12(b) of the Exchange Act. By examining items such as Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, and Regulation FD Disclosure, users can understand how Candel reports on its financial position, capital resources, and clinical program updates.
On Stock Titan, AI-powered tools can help summarize lengthy Candel filings, highlight key sections, and surface references to topics like CAN-2409, CAN-3110, the enLIGHTEN™ Discovery Platform, and regulatory designations. This allows readers to quickly identify information on term loan covenants, equity offerings, and clinical data disclosures without manually parsing each document.